Medicare spending on drugs with accelerated approval

JAMA Network

What The Study Did: This study found that Medicare spending from 2015 through 2019 on drugs with an accelerated approval indication doubled from $4.7 billion to $9.1 billion, with most of this growth among Part B drugs.

Authors: Benjamin N. Rome, M.D., M.P.H., of Brigham and Women’s Hospital in Boston, is the corresponding author.

To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/

(doi:10.1001/jamahealthforum.2021.3937)

/Public Release. This material from the originating organization/author(s) may be of a point-in-time nature, edited for clarity, style and length. The views and opinions expressed are those of the author(s).View in full here.